Cited by 92Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 229 of the 240 references it cites were found in a registry or an index.

The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer

Open access

Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita, Fasano, Rossella, Silvestris, Nicola, Baradaran, Behzad·2022·Biomedicine & Pharmacotherapy

DOI 10.1016/j.biopha.2021.112516

Open this paper in CoChat — free account Open PDF

Abstract

The growth and development of cancer are directly correlated to the suppression of the immune system. A major breakthrough in cancer immunotherapy depends on various mechanisms to detect immunosuppressive factors that inhibit anti-tumor immune responses. Immune checkpoints are expressed on many immune cells such as T-cells, regulatory B cells (Bregs), dendritic cells (DCs), natural killer cells (NKs), regulatory T (Tregs), M2-type macrophages, and myeloid-derived suppressor cells (MDSCs). Immune inhibitory molecules, including CTLA-4, TIM-3, TIGIT, PD-1, and LAG-3, normally inhibit immune responses via negatively regulating immune cell signaling pathways to prevent immune injury. However, the up-regulation of inhibitory immune checkpoints during tumor progression on immune cells suppresses anti-tumor immune responses and promotes immune escape in cancer. It has recently been indicated that cancer cells can up-regulate various pathways of the immune checkpoints. Therefore, targeting immune inhibitory molecules through antibodies or miRNAs is a promising therapeutic strategy and shows favorable results. Immune checkpoint inhibitors (ICIs) are introduced as a new immunotherapy strategy that enhance immune cell-induced antitumor responses in many patients. In this review, we highlighted the function of each immune checkpoint on different immune cells and therapeutic strategies aimed at using monoclonal antibodies and miRNAs against inhibitory receptors. We also discussed current challenges and future strategies for maximizing these FDA-approved immunosuppressants' effectiveness and clinical success in cancer treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2021.112516

Cites

229 of 229 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

TIGIT predominantly regulates the immune response via regulatory T cells
Kurtuluş, S., Sakuishi, K., Ngiow, S. F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 558
Retracted
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. I. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,818
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Yu, X., Harden, K., Gonzalez, L. C., Francesco, M. R., Chiang, E. Y., Irving, B. A., Tom, I., Ivelja, S., Refino, C. J., Clark, H. F., et al. (2008) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,536
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,382
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
André, P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,257
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,224
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,220
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.162 · Cited by 1,197
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,190
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,060
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,035
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P. A., Johnson, N. A., Brice, P., Radford, J. A., Ribrag, V., Molin, D. L., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 991
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Sangro, B., Gómez-Martín, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu‐Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 989
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 971
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Natural killer cells, viruses and cancer
Cerwenka, A., & Lanier, L. L. (2001) · Nature reviews. Immunology · doi:10.1038/35095564 · Cited by 874
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Chow, L. Q. M., Haddad, R. I., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B. A., Lee, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 868
Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Tumor-associated macrophages: from basic research to clinical application
Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Kochin, V., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 823
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M. F., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 805
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J. P., Alaparthy, S., Berman, D., Jure‐Kunkel, M., Siemers, N. O., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 783
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 760
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 721
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 689
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & TOKURA, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 668
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 640
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Yu, J., Du, W., Fang, Y., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 625
Immune Therapy for Cancer
Dougan, M. L., & Dranoff, G. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 625
Molecular regulation of effector and memory T cell differentiation
Chang, J. T., Wherry, E. J., & Goldrath, A. W. (2014) · Nature Immunology · doi:10.1038/ni.3031 · Cited by 604
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558
Clinical Challenges of Immune Checkpoint Inhibitors
Miguel, M. J. D., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 549
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 546
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Macrophage polarity in cancer: A review
Najafi, M., Goradel, N. H., Farhood, B., Salehi, E., Nashtaei, M. S., Khanlarkhani, N., Khezri, Z., Majidpoor, J., Abouzaripour, M., Habibi, M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27646 · Cited by 491
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Fengming, W., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 418
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
PD-1hi identifies a novel regulatory b-cell population in human hepatoma that promotes disease progression
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 345
TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C. (2013) · OncoImmunology · doi:10.4161/onci.23849 · Cited by 340
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 339
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research · doi:10.1038/cr.2017.90 · Cited by 328
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Wang, X., Li, J., Dong, K., Fang, L., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 318
Treating cancer with microRNA replacement therapy: A literature review
Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 313
Self-citation
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
Heeren, A. M., Punt, S., Bleeker, M. C. G., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 312
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., et al. (2018) · Blood · doi:10.1182/blood-2018-01-825265 · Cited by 300
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y. Q., Wang, T., Song, W., Chen, Y., Ouyang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 290
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G. M., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 287
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Rosenblatt, J. M., Glotzbecker, B. E., Mills, H., Vasir, B., Tzachanis, D., Levine, J. D., Joyce, R., Wellenstein, K., Keefe, W., Schickler, M., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821ca6ce · Cited by 284
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A. J., & Weber, J. S. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 282
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prébet, T., Charbonnier, A., Etienne, A., André, P., Romagné, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 277
Mouse TIGIT inhibits NK ‐cell cytotoxicity upon interaction with PVR
Stanietsky, N., Roviš, T. L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R., Enk, J., Jonjić, S., & Mandelboim, O. (2013) · European Journal of Immunology · doi:10.1002/eji.201243072 · Cited by 269
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J. N., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 269
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
Fuhrman, C. A., Yeh, W.-I., Seay, H. R., Lakshmi, P. S., Chopra, G., Zhang, L., Perry, D. J., McClymont, S., Yadav, M., Lopez, M.-C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402381 · Cited by 267
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A. E., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 267
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 265
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Hawkins, R. E., & Thistlethwaite, F. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2870 · Cited by 253
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 242
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 241
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Zhao, L., Yu, H., Yi, S., Peng, X., Su, P., Xiao, Z., Liu, R., Tang, A., Li, X., Liu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9659 · Cited by 227
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Xu, L., Huang, Y., Tan, L., Yu, W., Chen, D., Lu, C., He, J.-Y., Wu, G., Liu, X., & Zhang, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.017 · Cited by 224
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
Wu, L., Mao, L., Liu, J., Chen, L., Yu, G., Yang, L., Wu, H., Bu, L., Kulkarni, A. B., Zhang, W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0725 · Cited by 223
Regulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 218
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
Gianchecchi, E., & Fierabracci, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02374 · Cited by 214
VISTA expressed in tumour cells regulates T cell function
Mulati, K., Hamanishi, J., Matsumura, N., Chamoto, K., Mise, N., Abiko, K., Baba, T., Yamaguchi, K. D., Horikawa, N., Murakami, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0313-5 · Cited by 211
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
Osta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 208
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
Wei, J., Nduom, E. K.-E., Kong, L.-Y., Hashimoto, Y., Xu, S., Gabrusiewicz, K. R., Ling, X., Huang, N., Qiao, W., Zhou, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov292 · Cited by 199
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
Gill, S. I., Vasey, A. E., Souza, A. D., Baker, J. B., Smith, A. T., Kohrt, H. E. K., Florek, M., Gibbs, K. D., Tate, K. M., Ritchie, D. S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415364 · Cited by 198
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Sarhan, D., Cichocki, F. M., Zhang, B., Yingst, A. M., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 198
B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Yao, Y., Ye, H., Qi, Z., Mo, L., Qi, Y., Baral, A., Hoon, D. S. �., Vera, J. C., Heiss, J. D., Chen, C. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0858 · Cited by 190
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression
Xu, W., Dong, J., Zheng, Y., Zhou, J., Yuan, Y., Ta, H. M., Miller, H. E., Olson, M., Rajasekaran, K., Ernstoff, M. S., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0489 · Cited by 190
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 189
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Yan, J., Zhang, Y., Zhang, J., Liang, J., Li, L., & Zheng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058006 · Cited by 188
Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
Ma, S., Deng, W., Liu, J., Mao, L., Yu, G., Bu, L., Kulkarni, A. B., Zhang, W., & Sun, Z. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0665-0 · Cited by 183
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lü, L., Xu, X., Zhang, B., Zhang, R., Ji, H., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-36 · Cited by 182
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. C., & Cerwenka, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302091 · Cited by 181
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
Wang, L., Jia, B., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Naik, S. G., Khawaja, M. R., Sivik, J., Han, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1469594 · Cited by 181
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
Tinoco, R., Carrette, F., Henriquez, M. L., Otero, D. C., Magaña, J., Bosenberg, M., Swain, S. L., & Bradley, L. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.015 · Cited by 179
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
Lichtenegger, F. S., Rothe, M., Schnorfeil, F. M., Deiser, K., Krupka, C., Augsberger, C., Schlüter, M., Neitz, J. S., & Subklewe, M. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00385 · Cited by 178
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Ribas, A., Butler, M. O., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W. H., Linette, G. P., Ascierto, P. A., Kuzel, T. M., Algazi, A. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3003 · Cited by 158
PSGL-1: A New Player in the Immune Checkpoint Landscape
Tinoco, R., Otero, D. C., Takahashi, A. A., & Bradley, L. M. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.002 · Cited by 155
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Xu, F., Sunderland, A., Zhou, Y., Schulick, R. D., Edil, B. H., & Zhu, Y. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2031-x · Cited by 152
Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210
Noman, M. Z., Janji, B., Hu, S., Wu, J. C., Martelli, F., Bronte, V., & Chouaı̈b, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0405 · Cited by 149
Inhibition of natural killer cell activation signals by killer cell immunoglobulin‐like receptors (CD158)
Long, E. O., Barber, D. F., Burshtyn, D. N., Faure, M., Peterson, M., Rajagopalan, S., Renard, V., Sandusky, M., Stebbins, C. C., Wagtmann, N. R., et al. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1810119.x · Cited by 146
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 145
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
McWilliams, E. M., Mele, J. M., Cheney, C. M., Timmerman, E. A., Fiazuddin, F., Strattan, E., Mo, X. M., Byrd, J. C., Muthusamy, N., & Awan, F. T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1226720 · Cited by 144
Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
Kim, S. H., Li, M., Trousil, S., Zhang, Y., di Magliano, M. P., Swanson, K. D., & Zheng, B. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.033 · Cited by 142
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway
Wang, X., Wang, G., Wang, Z., Liu, B., Han, N., Li, J., Lu, C., Liu, X., Zhang, Q., Yang, Q., et al. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.02.009 · Cited by 142
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
Kondo, Y., Ohno, T., Nishii, N., Harada, K., Yagita∥, H., & Azuma, M. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.04.005 · Cited by 141
PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Han, X. N., Vesely, M. D., Yang, W., Sanmamed, M. F., Badri, T., Alawa, J., López‐Giráldez, F., Gaule, P., Lee, S. W., Zhang, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax1159 · Cited by 139
Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy
Cai, D., Li, J., Liu, D., Hong, S., Qiao, Q., Sun, Q., Li, P., Lyu, N., Sun, T., Xie, S., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0305-2 · Cited by 136
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 135
Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
Liu, J., Wu, L., Yang, L., Deng, W., Mao, L., Wu, H., Zhang, W., & Sun, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0713-7 · Cited by 133
miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion
Li, Q., Johnston, N., Zheng, X., Wang, H., Zhang, X., Gao, D., & Min, W. (2016) · Oncotarget · doi:10.18632/oncotarget.10731 · Cited by 132
Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes
Elpek, K. G., Rubinstein, M. P., Bellemare-Pelletier, A., Goldrath, A. W., & Turley, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012128107 · Cited by 130
T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 122
Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses
Zhang, Y. X., Morgan, R., Chen, C., Cai, Y., Clark, E., Khan, W. N., Shin, S.-U., Cho, H.-M., Bayati, A. A., Pimentel, A., et al. (2016) · International Immunology · doi:10.1093/intimm/dxw007 · Cited by 120
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Immune checkpoint blockade opens a new way to cancer immunotherapy
Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 119
Self-citation
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
DiDomenico, J. D., Lamano, J. B., Oyon, D. E., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 118
MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3
Zhao, J. Y., Lei, T., Xu, C., Li, H., Ma, W., Yang, Y., Fan, S., & Liu, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.095 · Cited by 116
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0819-1 · Cited by 112
SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy
Jiang, K., Li, J., Zhang, J., Wang, L., Zhang, Q., Ge, J., Guo, Y., Wang, B., Huang, Y., Yang, T., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105818 · Cited by 107
Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis
Jiang, X., Zhou, T., Xiao, Y., Yu, J., Dou, S., Chen, G., Wang, R., He, X., Hou, C., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1211219 · Cited by 106
PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
Zelba, H., Bedke, J., Hennenlotter, J., Mostböck, S., Zettl, M., Zichner, T., Chandran, A., Stenzl, A., Rammensee, H., & Gouttefangeas, C. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0146 · Cited by 105
MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their Function
Fayyad‐Kazan, H., Rouas, R., Fayyad‐Kazan, M., Badran, R., Zein, N. E., Lewalle, P., Najar, M., Hamade, E., Jebbawi, F., Merimi, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.337154 · Cited by 104
A novel MDSC-induced PD-1 − PD-L1 + B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties
Shen, M., Wang, J., Yu, W., Zhang, C., Liu, M., Wang, K., Yang, L., Wei, F., Wang, S. E., Sun, Q., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1413520 · Cited by 104
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 103
Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3
Schneider, T., Hoffmann, H., Dienemann, H., Schnabel, P. A., Enk, A., Ring, S., & Mahnke, K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821c421d · Cited by 98
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
Park, H., Kusnadi, A., Lee, E., Kim, W. W., Cho, B. C., Lee, I. J., Seong, J., & Ha, S. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.001 · Cited by 91
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 91
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint
Tao, Z., Xu, S., Ruan, H., Wang, T., Song, W., Li, Q., & Chen, K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491909 · Cited by 91
Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis
Shiau, D.-J., Kuo, W., Davuluri, G. V. N., Shieh, C.-C. K., Tsai, P.-J., Chen, C., Lin, Y.-S., Wu, Y.-Z., Hsiao, Y.-P., & Chang, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-70137-4 · Cited by 91
Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections
Ha, S., West, E. E., Araki, K., Smith, K. A., & Ahmed, R. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00638.x · Cited by 90
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 90
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
Self-citation
Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression
Amobi, A. E., Qian, F., Lugade, A. A., & Odunsi, K. O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_9 · Cited by 90
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Wang, Z., Zhu, J., Gu, H., Yuan, Y., Zhang, B., Zhu, D., Zhou, J., Zhu, Y., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1052145 · Cited by 82
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
Grywalska, E., Pasiarski, M., Góźdź, S. S., & Roliński, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150817 · Cited by 82
Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine
Derakhshani, A., Hashemzadeh, S., Asadzadeh, Z., Shadbad, M. A., Rasibonab, F., Safarpour, H., Jafarlou, V., Solimando, A. G., Racanelli, V., Singh, P., et al. (2021) · Cancers · doi:10.3390/cancers13102414 · Cited by 81
Self-citation
MiR‐15a/16 deficiency enhances anti‐tumor immunity of glioma‐infiltrating CD8+ T cells through targeting mTOR
Yang, J., Liu, R., Deng, Y., Qian, J., Lu, Z., Wang, Y., Zhang, D., Luo, F., & Chu, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.30912 · Cited by 79
Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma
Jasinski‐Bergner, S., Stoehr, R., Bukur, J., Massa, C., Braun, J., Hüttelmaier, S., Spath, V., Wartenberg, R., Legal, W., Taubert, H. W., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008805 · Cited by 76
Clinical significance of programmed cell death‐ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability
Korehisa, S., Oki, E., Iimori, M., Nakaji, Y., Shimokawa, M., Saeki, H., Okano, S., Oda, Y., & Maehara, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.31107 · Cited by 76
Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
Yang, S., Cao, B., Zhou, G., Zhu, L., Wang, L., Zhang, L., Kwok, H. F., Zhang, Z., & Zhao, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01089 · Cited by 76
Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.
Wei, T., Zhang, J., Qin, Y., Wu, Y. C., Zhu, L. X., Lu, L., Tang, G., & Shen, Q. (2015) · Europe PMC (PubMed Central) · Cited by 73
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 73
The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy
Endo, R., Nakamura, T., Kawakami, K., Sato, Y., & Harashima, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47799-w · Cited by 72
B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy
Cheng, N., Bei, Y., Song, Y., Zhang, W., Xu, L., Zhang, W., Yang, N., Bai, X., Shu, Y., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114298 · Cited by 72
Depleting Tumor-Associated Tregs Via Nanoparticle-Mediated Hyperthermia to Enhance Anti-CTLA-4 Immunotherapy
Chen, H., Luan, X., Paholak, H. J., Burnett, J., Stevers, N. O., Sansanaphongpricha, K., He, M., Chang, A. E., Li, Q., & Sun, D. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0190 · Cited by 71
Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
Audenaerde, J. R. M. V., Waele, J. D., Marcq, E., Loenhout, J. V., Lion, E., den Bergh, J. M. J. V., Jesenofsky, R., Masamune, A., Roeyen, G., Pauwels, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18185 · Cited by 69
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages
Jiang, C., Yuan, F., Wang, J., & Wu, L. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.12.002 · Cited by 69
Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 69
Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68
VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis
Ceeraz, S., Sergent, P. A., Plummer, S. F., Schned, A. R., Pechenick, D. A., Burns, C. M., & Noelle, R. J. (2016) · Arthritis & Rheumatology · doi:10.1002/art.40020 · Cited by 68
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead
Hosseinkhani, N., Derakhshani, A., Shadbad, M. A., Argentiero, A., Racanelli, V., Kazemi, T., Mokhtarzadeh, A., Brunetti, O., Silvestris, N., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676181 · Cited by 68
Self-citation
CD8+ T cells exhaustion induced by myeloid‐derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal‐9 pathway
Tao, J., Han, D., Gao, S., Zhang, W., Yu, H., Liu, P., Fu, R., Li, L., & Shao, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14825 · Cited by 67
Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways
Park, A., Yang, Y., Lee, Y., Kim, M. S., Park, Y., Jung, H., Kim, T., Lee, H. G., Choi, I., & Yoon, S. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060842 · Cited by 66
MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma
Wang, Y., Wang, D., Xie, G., Yin, Y., Zhao, E., Tao, K., & Li, R. (2017) · Oncotarget · doi:10.18632/oncotarget.15924 · Cited by 64
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 61
IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery
Qian, S., Zhang, M., Chen, Q., He, Y., Wang, W., & Wang, Z. (2016) · RSC Advances · doi:10.1039/c5ra25046c · Cited by 61
MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling
Ji, X., Wang, E., & Tian, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.120 · Cited by 56
Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma
Chang, W., Li, C.-H., Chu, L.-H., Huang, P.-S., Sheu, B., & Huang, S. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000578 · Cited by 56
Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy
Funes, S. C., de Lara, A. M., Altamirano-Lagos, M. J., Mackern‐Oberti, J. P., Escobar‐Vera, J., & Kalergis, A. M. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.02.006 · Cited by 55
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer
Guan, Y., Zhang, R., Peng, Z., Dong, D., Wei, G., & Wang, Y. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.10.002 · Cited by 54
PD-1+ Treg cells: a foe in cancer immunotherapy?
Aksoylar, H., & Boussiotis, V. A. (2020) · Nature Immunology · doi:10.1038/s41590-020-0801-7 · Cited by 53
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7
Halpert, M. M., Konduri, V., Liang, D., Chen, Y., Wing, J. B., Paust, S., Levitt, J. M., & Decker, W. K. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0009 · Cited by 52
Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression
Skafi, N., Fayyad‐Kazan, M., & Badran, B. M. (2020) · Gene · doi:10.1016/j.gene.2020.144888 · Cited by 52
BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma
Zhao, Q., Huang, Z., He, M. Y., Gao, Z., & Kuang, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1254855 · Cited by 49
Concomitant blockade of A2AR and CTLA‐4 by siRNA‐loaded polyethylene glycol‐chitosan‐alginate nanoparticles synergistically enhances antitumor T‐cell responses
Ghasemi‐Chaleshtari, M., Kiaie, S. H., Irandoust, M., Karami, H., Nabi‐Afjadi, M., Ghani, S., Vanda, N. A., Sede, M. J. G., Ahmadi, A., Masjedi, A., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29822 · Cited by 49
Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge
Naboush, A., Roman, C. A. J., & Shapira, I. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000342 · Cited by 48
Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma
Boldrini, L., Giordano, M., Niccoli, C., Melfi, F. M. A., Lucchi, M., Mussi, A., & Fontanini, G. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0474-y · Cited by 47
Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
Karihtala, K., Leivonen, S., Brück, O. E., Karjalainen‐Lindsberg, M., Mustjoki, S. M., Pellinen, T. S., & Leppä, S. (2020) · Cancers · doi:10.3390/cancers12040877 · Cited by 47
MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma
Guo, W., Tan, W., Liu, S., Huang, X., Lin, J., Liang, R., Su, L., Su, Q., & Wang, C. (2015) · Tumor Biology · doi:10.1007/s13277-015-3644-3 · Cited by 46
Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation
Sato, N., Saga, Y., Mizukami, H., WANG, D., Takahashi, S., NONAKA, H., Fujiwara, H., Takei, Y., 町田, 静., Takikawa, O., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1984 · Cited by 46
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103 + dendritic cells in late-stage ovarian cancer
Flies, D. B., Higuchi, T., Harris, J. C., Jha, V., Gimotty, P. A., & Adams, S. F. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1185583 · Cited by 44

Research works printed but not linked: 1

Cutolo, 2013, NF-κB decrease and IKBα increase in human macrophages following CTLA4-Ig treatment, Clin. Exp. Rheumatol., 31, 943

Sorted by citations

Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 338
“Immune checkpoints are modulators of the immune system that either promote (co-stimulatory molecules) or stop signaling (co-inhibitory molecules) in immune cells and control their activity, thus, playing a crucial role in maintaining immune homeostasis in immune cells.(368,369) The first immune checkpoint molecule, cy…”
Background
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Rangraze, I. R., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A. A., Rizzo, M., El‐Tanani, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216894 · Cited by 212
Exosome-Mediated Immunosuppression in Tumor Microenvironments
Xie, Q., Zheng, J.-Q., Ding, J., Wu, Y.-F., Liu, L., Yu, Z., & Chen, G. (2022) · Cells · doi:10.3390/cells11121946 · Cited by 144
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
Fakih, M., Raghav, K. P. S., Chang, D. Z., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Tam, R., D’Adamo, D. R., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101917 · Cited by 127
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 73

See all 92

Authors: Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., Fasano, R., Silvestris, N., & Baradaran, B.
Affiliations: University of Tabriz (IR)
Tabriz University of Medical Sciences (IR)
Birjand University of Medical Sciences (IR)
University of Catania (IT)
Istituto Tumori Bari (IT)
Corresponding author: Silvestris, Nicola
Baradaran, Behzad
ORCID: Asadzadeh, Zahra
Baghbanzadeh, Amir
Ghorbaninezhad, Farid
Safarpour, Hossein
Bernardini, Renato
Brunetti, Oronzo
Fasano, Rossella
Silvestris, Nicola
Baradaran, Behzad
Venue: Biomedicine & Pharmacotherapy
Publisher: Elsevier BV
Published: 2022-02
Volume: 146
Pages: 112516
ISSN: 0753-3322 (ISSN-L)
DOI: 10.1016/j.biopha.2021.112516
OpenAlex: W4200317153
Cited by: 92
References: 240
Citations by year: 2026: 8 · 2025: 21 · 2024: 26 · 2023: 21 · 2022: 16
FWCI: 1.91
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Biomedicine & Pharmacotherapy (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune checkpoint, cancer immunotherapy, immune checkpoint inhibitors, tumor immune evasion, CTLA-4, PD-1, TIM-3, TIGIT, LAG-3, regulatory T cells, myeloid-derived suppressor cells, regulatory B cells, dendritic cells, natural killer cells, monoclonal antibodies, microRNA, antitumor immunity
MeSH terms: Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Immune Checkpoint Proteins, Neoplasms, Monitoring, Immunologic, Signal Transduction, Down-Regulation, Up-Regulation, Tumor Escape, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks